Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for daytime sleep in shift workers
NCT02491788Phase 4Completed
- Sponsor
- VA Palo Alto Health Care System
- Start
- Feb 2016
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in circadian rhythm sleep-wake disorder (CRSWD) comparing Suvorexant with Placebo (2 arms). Primary endpoint: Change in Average Total Sleep Time at 3 weeks. Started Feb 2016; status: completed.
02
Drugs
suvorexant
03
Conditions
circadian rhythm sleep-wake disorder (CRSWD)
Beyond the preview
Go deeper on NCT02491788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02491788.